US › Healthcare

Abeona Therapeutics Inc (ABEO)

US · Healthcare · Biotechnology

$5.59+4.10%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$11.4M

Revenue YoY

+2745.0%

Net profit

$-20.2M

Profit YoY

-118.6%

EPS

$-0.35

EPS estimate

$-0.23

Net margin

-177.4%

EPS came in at -0.35 against a street estimate of -0.23 — a miss of 52.2%.

Key statistics

Market cap

$307.1M

Forward P/E

18.7

P/B

2.45

Book value

$2.24

EPS (TTM)

$-1.21

52-week high

$7.65

52-week low

$4.00

50-day MA

$6.34

200-day MA

$5.53

Beta

1.32

Analyst view

Analysts rate Abeona Therapeutics Inc a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $18.86.

Shareholding

Insiders

16.46%

Institutions

69.74%

Largest institutional holders

Fund	Stake
Nantahala Capital Management, LLC	8.77%
BlackRock Inc	5.59%
Cable Car Capital LLC	5.26%
AIGH Capital Management, LLC	5.22%
Suvretta Capital Management, LLC	4.68%
Vanguard Capital Management, LLC	3.79%
Resources Investment Advisors Inc	2.89%
Kennedy Capital Management Inc	2.17%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Abeona Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.